Anaptysbio Inc share price logo

Anaptysbio Inc Share Price

NASDAQ: ANAB

Small Cap

$63.05

+0.33

(+0.53%)

as on

Anaptysbio Inc Stock Performance

as on March 25, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $60.96
    $64.00
    downward going graph

    3.31%

    Downside

    1.51%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $15.40
    $68.39
    downward going graph

    75.57%

    Downside

    8.47%

    Upside

    downward going graph

Anaptysbio Inc share price movements today

Previous Close
$62.72
Open
$62.38
Volume
262.1K
Day's Low - High
$60.96 - $64.00
52 Week Low - High
$15.40 - $68.39

Anaptysbio Inc Historical Returns

1 Month Return
+ 14.87 %
3 Month Return
+ 24.63 %
1 Year Return
+ 265.13 %
3 Year Return
+ 188.33 %
5 Year Return
+ 197.83 %

Anaptysbio Inc Stock Fundamentals & Key Indicators

Check Anaptysbio Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.8B

EPS (TTM)

-4.0195

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-5.91

Industry PE ratio

-4.738881355932204

PEG Ratio

0

EBITDA

48.5M

Revenue (TTM)

234.6M

Profit Margin

-5.64%

Return On Equity TTM

-24.49%

Anaptysbio Inc Stock Valuation

Track how Anaptysbio Inc P/E has moved over time to understand its valuation trends.

Anaptysbio Inc in the last 5 years

  • Overview

  • Trends

Lowest (-74.97x)

December 31, 2025

Today (-5.91x)

March 23, 2026

Industry (-4.74x)

March 23, 2026

Highest (90.65x)

September 30, 2021

LowHigh

Today’s Price to Earnings Ratio: -5.91x

Anaptysbio Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Anaptysbio Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Anaptysbio Inc image
Anaptysbio Inc
BUY$1.8B197.83%-5.91-5.64%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.4B125.13%133.418.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.3B112.56%29.6732.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.6BNA1115.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$77.5B56.01%17.6731.41%

Stock Returns calculator for Anaptysbio Inc Stock including INR - Dollar returns

The Anaptysbio Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Anaptysbio Inc investment value today

Current value as on today

₹3,78,686

Returns

₹2,78,686

(+278.69%)

Returns from Anaptysbio Inc Stock

₹2,69,145 (+269.15%)

Dollar Returns*

₹9,541 (+9.54%)

Analyst Recommendation on Anaptysbio Inc Stock

Based on 16 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 16 analysts, 75% of analysts recommend a 'BUY' rating for Anaptysbio Inc. Average target price of $78.25

Anaptysbio Inc Share Price Target

Get share price movements and forecasts by analysts on Anaptysbio Inc.

What analysts predicted

19.42%UPSIDE

Target Price

$78.25

Current Price

$63.05

Analyzed by

16 Analysts

Target

$78.25

Anaptysbio Inc target price $78.25, a slight upside of 19.42% compared to current price of $63.05. According to 16 analysts rating.

Anaptysbio Inc Stock’s Investor Sentiment and Interest

Search interest for Anaptysbio Inc Stock has decreased by -10% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-10% versus previous 30 day period

Anaptysbio Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
3
9
7
10
30
43
27
22
76
108
Gross Profit
-27
-24
-29
-31
-12
0
-13
-15
44
216
Operating Income
-37
-42
-42
-40
-22
-9
-27
-26
34
66
EBITDA
-32
-34
-37
-35
-16
-3
-20
-18
38
67
Interest Expense
4
4
6
10
15
17
18
19
22
19
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-37
-42
-43
-46
-32
-21
-39
-38
15
49
Income Tax Expense
4
0
0
0
0
0
0
0
-
0
Net Income
-37
-42
-43
-46
-32
-21
-39
-38
15
49
Net Profit Margin
-1124.41%
-468.75%
-612.01%
-425.30%
-109.44%
-50.53%
-141.62%
-173.52%
19.80%
45.83%

Anaptysbio Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
16
10
5
8
75
63
10
17
91
234
Gross Profit
1
-19
-51
-91
-5
-35
-78
-115
-72
232
Operating Income
-3
-28
-66
-107
-23
-56
-115
-164
-114
47
EBITDA
-3
-28
-59
-95
-19
-55
-105
-156
-92
50
Interest Expense
0
1
1
1
3
1
21
18
50
79
Depreciation
-
0
0
0
0
2
2
2
2
2
Income Before Tax
-4
-30
-61
-97
-19
-57
-128
-163
-145
-13
Income Tax Expense
0
1
0
0
0
0
0
0
0
0
Net Income
-4
-30
-61
-97
-19
-57
-128
-163
-145
-13
Net Profit Margin
-25.53%
-300.70%
-1233.12%
-1216.70%
-26.57%
-91.49%
-1251.33%
-953.66%
-159.10%
-5.64%

Anaptysbio Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-42
-43
-46
-32
-21
-39
-38
15
49
Operating Cash Flow
-34
-37
-21
-10
-66
-10
-40
-27
97
Investing Cash Flow
49
68
-2
58
-29
14
36
103
73
Financing Cash Flow
-5
-13
41
71
27
-28
-50
-10
-43
Change in Cash
9
17
18
119
-68
-24
-54
65
128

Anaptysbio Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-30
-61
-97
-19
-57
-128
-163
-145
49
Operating Cash Flow
-19
-48
-69
-14
-45
-73
-120
-135
19
Investing Cash Flow
-243
-142
131
94
38
-394
144
95
228
Financing Cash Flow
292
223
-4
0
252
44
-59
127
-132
Change in Cash
29
32
57
79
245
-424
-35
87
115

Global Institutional Holdings in Anaptysbio Inc

Funds
Holdings
BlackRock Inc
5.99%
Point72 Asset Management, L.P.
7.88%
UBS Group AG
4.55%
Palo Alto Investors, LLC
2.4%
Millennium Management LLC
2.83%
See all

Anaptysbio Inc News & Key Events

  • img

    Today's Timeline - 21 November

    Fri, 07:16 PM

    -

    AnaptysBio's stock fell 12% after Tesaro announced a lawsuit for alleged breach of license agreement regarding Jemperli.

    Fri, 07:18 PM

    -

    Tesaro's lawsuit claims AnaptysBio breached the license agreement for Jemperli, potentially terminating the agreement and reducing payments.

Insights on Anaptysbio Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, ANAB stock has moved up by 13.2%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ANAB has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ANAB has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 4 quarters, -39.32M → 49.61M (in $), with an average increase of 142.3% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 22.26M → 108.24M (in $), with an average increase of 50.2% per quarter

About Anaptysbio Inc

founded in 2005, anaptysbio, inc. is a privately-held company focused on the generation of antibody therapeutics, and the leader in the use of somatic hypermutation (shm) for antibody discovery and optimization. anaptysbio is building a pipeline of novel therapeutic antibody product candidates, including differentiated programs in cancer immunotherapy, inflammation, muscle wasting disorders, fibrosis and antibody-drug conjugate applications. anaptysbio’s proprietary shm-xel platform, which couples fully human antibody libraries with in vitro somatic hypermutation (shm) in mammalian cells to generate high affinity lead candidates, replicates key features of the human immune system and overcomes limitations of prior antibody technologies. by harnessing the natural mechanism of antibody maturation under controlled conditions, shm-xel allows for the selection of optimal antibody properties such as high affinity, function, cross-reactivity, epitope diversity and manufacturability. the c
OrganisationAnaptysbio Inc
Headquarters10770 Wateridge Circle, San Diego, CA, United States, 92121-5801
IndustryHealth Technology
CEOMr. Daniel R. Faga
E-voting on sharesClick here to vote

Key Management of Anaptysbio Inc

Name

Title

Mr. Dennis M. Mulroy

Chief Financial Officer

Mr. Eric J. Loumeau

Chief Legal Officer

Dr. Martin Dahl Ph.D.

Senior Vice President of Research

Ms. Monique Da Silva

Senior Vice President of Corporate Affairs

Ms. Cailin Sibley FACR, M.D.

Senior Vice President of Translational Medicine

Mr. Daniel R. Faga

President, CEO & Director

Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D.

Chief Medical Officer

Ms. Beth Mueller

Senior Vice President of Human Resources

Mr. Benjamin Stone

Chief Business Officer

Ms. Priya Raina

Senior Vice President of Clinical Operations

FAQs

What is Anaptysbio Inc share price today?

Anaptysbio Inc share price today is $63.05 as on at the close of the market. Anaptysbio Inc share today touched a day high of $64 and a low of $60.96.

What is the 52 week high and 52 week low for Anaptysbio Inc share?

Anaptysbio Inc share touched a 52 week high of $68.39 on and a 52 week low of $15.4 on . Anaptysbio Inc stock price today i.e. is closed at $63.05,which is 7.81% down from its 52 week high and 309.42% up from its 52 week low.

What is Anaptysbio Inc's market capitalisation today?

Anaptysbio Inc market capitalisation is $0.00T as on .

How to invest in Anaptysbio Inc Stock (ANAB) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Anaptysbio Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Anaptysbio Inc Shares that will get you 0.0238 shares as per Anaptysbio Inc share price of $63.05 per share as on March 25, 2026 at 1:29 am IST.

What is the minimum amount required to buy Anaptysbio Inc Stock (ANAB) from India?

Indian investors can start investing in Anaptysbio Inc (ANAB) shares with as little as ₹93.734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹937.34 in Anaptysbio Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Anaptysbio Inc share’s latest price of $63.05 as on March 25, 2026 at 1:29 am IST, you will get 0.1586 shares of Anaptysbio Inc. Learn more about fractional shares .

What are the returns that Anaptysbio Inc has given to Indian investors in the last 5 years?

Anaptysbio Inc stock has given 197.83% share price returns and 28.4% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?